2,460 Eli Lilly and Company $LLY Shares Sold by BOCHK Asset Management Ltd

Key Points

• BOCHK Asset Management cut its Eli Lilly stake by 37.2%, selling 2,460 shares in the third quarter and retaining 4,150 shares valued at about $4.8 million.
• Lilly reported quarterly EPS of $7.48 and revenue of $24.4 billion, beating analyst estimates; revenue grew 38.6% year over year.
• Analyst sentiment remains broadly positive: 24 analysts rated the stock a Buy, and its consensus price target was $1,404.14.

BOCHK Asset Management Ltd cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 37.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,150 shares of the company's stock after selling 2,460 shares during the quarter. BOCHK Asset Management Ltd's holdings in Eli Lilly and Company were worth $4,802,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Integrity Financial Corp WA lifted its stake in Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after purchasing an additional 8 shares during the last quarter. LCM Capital Management Inc grew its stake in shares of Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company's stock valued at $293,000 after buying an additional 8 shares during the last quarter. Smith Shellnut Wilson LLC ADV grew its stake in shares of Eli Lilly and Company by 4.1% during the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company's stock valued at $235,000 after buying an additional 8 shares during the last quarter. Financial Network Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 5.6% in the third quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company's stock worth $175,000 after buying an additional 8 shares during the period. Finally, Willner & Heller LLC increased its holdings in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after buying an additional 9 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,408.68 on Wednesday. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 44.16, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company has a 50-day moving average price of $1,204.03 and a 200-day moving average price of $1,095.92. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company's revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the prior year, the business posted $7.02 earnings per share. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.61 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is 22.46%.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 18,500 shares of company stock worth $22,970,770. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research note on Friday, October 30th. Citigroup raised their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research note on Monday. HSBC boosted their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,404.14.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.